Assessing Genetic Risk in Early-Onset Fetal Growth Restriction Using Placental Markers

Managing early-onset fetal growth restriction (FGR) requires precise tools to determine underlying causes. A recent study highlights how placental insufficiency markers can evaluate the fetal growth restriction genetic risk. Researchers analyzed pregnancies where growth was severely limited before 29 weeks of gestation. Specifically, they looked at cases where the estimated fetal weight was at or below the 3rd percentile.

The soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) ratio typically serves as a proxy for placental health. However, a lower ratio in these high-risk cases suggests a higher probability of non-chromosomal genetic abnormalities. When placental markers appear relatively normal, the restriction may stem from intrinsic fetal factors rather than placental dysfunction. Consequently, clinicians might need to prioritize advanced genetic testing like chromosomal microarray (CMA) or whole-exome sequencing (WES) in these specific scenarios.

Triage for Fetal Growth Restriction Genetic Risk

Furthermore, the data indicates that stratifying patients by their sFlt-1/PlGF ratio improves diagnostic yield. Mothers with low ratios had a significantly higher rate of pathogenic genetic variants in their fetuses. This finding is particularly relevant for Indian clinicians who often balance the costs and benefits of invasive prenatal testing. Moreover, identifying these markers early can guide parental counseling and neonatal management plans effectively.

Additionally, the study emphasizes that even when ultrasound findings are isolated, the absence of placental insufficiency should raise suspicion. If the placenta appears to be functioning well biochemically, the growth restriction is likely secondary to a genetic condition. Therefore, integrating these biomarkers into routine protocols could refine the selection of candidates for exome sequencing.

Frequently Asked Questions

How does the sFlt-1/PlGF ratio relate to genetic risk in FGR?

A high sFlt-1/PlGF ratio indicates placental insufficiency. Conversely, a low ratio in severe FGR suggests the cause might be genetic rather than placental, increasing the likelihood of finding anomalies through CMA or WES.

When should clinicians consider whole-exome sequencing in FGR cases?

Clinicians should consider WES when early-onset FGR is severe (\u22643rd percentile) and placental markers like the sFlt-1/PlGF ratio are within normal limits, as this combination points toward a higher genetic risk.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

• Armengol-Alsina M et al. Placental insufficiency markers to assess the risk of non-chromosomal genetic conditions in early-onset fetal growth restriction. Ultrasound Obstet Gynecol. 2026 Mar 30. doi: 10.1002/uog.70211. PMID: 41906976.


• Nawathe A, Lees C. Early onset fetal growth restriction. Best Pract Res Clin Obstet Gynaecol. 2017;38:86-96.


• ISUOG Practice Guidelines: Diagnosis and management of fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56(2):298-312.